Newly issued patent expected to provide protection until at least 2041 and includes composition of matter claims to pharmaceutical compositions within the Company’s proprietary CYB003 deuterated psilocybin analog program – – Cybin’s patent portfolio now includes 39 granted patents and over 170 pending applications – – Recently announced positive topline data from Phase 2 study of CYB003 in major depressive disorder showed 79% of patients in remission after two 12mg doses –
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that the United States Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,834,410 in support of its CYB003 program.
The patent, which is expected to provide exclusivity until at least 2041, includes composition of matter claims to pharmaceutical compositions within the Company’s proprietary deuterated psilocybin analog program, CYB003, as well as claims directed toward the therapeutic treatment of major depressive disorder (“MDD”), treatment-resistant depression, and alcohol use disorder.
“Securing robust patent protection for our proprietary products is a top priority, and we are pleased to announce this additional U.S. patent supporting our CYB003 program. Last week, we shared positive Phase 2 topline safety and efficacy data for CYB003 in MDD. In addition to the rapid, robust and statistically significant reduction in depression symptoms observed three weeks following a single 12 milligram dose of CYB003 compared to placebo, we also saw a sustained improvement at six weeks, as well as impressive response and remission rates of 79% for patients who received two doses. We are extremely pleased with the data and the potential to deliver meaningfully improved treatment options for people with mental health disorders and are eager to progress our CYB003 program through the next regulatory steps.”
-Doug Drysdale, Chief Executive Officer of Cybin
About Cybin
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.
Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.
Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.